StocksMedium•10 November 2026•
1 min read
Waters Corp Receives FDA Clearance for Leukemia and Lymphoma Diagnostic Tests
Key Facts
1Waters Corporation received FDA 510(k) clearance for BD OneFlow LST and B-CLPD T1 tests used in identifying leukemia and lymphoma.
2The new tests demonstrate 96.3% sensitivity and 98.2% specificity in identifying chronic lymphocytic leukemia (CLL).
3The all-in-one solution reduces manual steps by 95%, improving workflow efficiency and reducing errors.
Waters Corporation received FDA 510(k) clearance for its BD OneFlow LST and B-CLPD T1 clinical tests used in identifying leukemia and lymphoma. PR Newswire reported that the standardized, ready-to-use flow cytometry tests are designed to aid in the diagnosis of B-cell non-Hodgkin lymphoma, providing faster and more reliable diagnostic insights.
The new tests demonstrate 96.3% sensitivity and 98.2% specificity in identifying chronic lymphocytic leukemia (CLL) while reducing manual laboratory steps by 95% to improve workflow efficiency. Shares of Waters Corporation, ticker WAT, closed at $476.70 on November 9, 2026, prior to the announcement of the regulatory clearance.